Scynexis Inc
NASDAQ:SCYX 1:11:17 PM EDT
Products
Scynexis Announces U.S. FDA Acceptance And Priority Review Of The Supplemental New Drug Application For Brexafemme® (Ibrexafungerp Tablets) For Prevention Of Recurrent Vaginal Yeast Infections
Published: 08/01/2022 14:38 GMT
Scynexis Inc (SCYX) - Scynexis Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for Brexafemme® (ibrexafungerp Tablets) for Prevention of Recurrent Vaginal Yeast Infections.
Scynexis Inc - Submission Has Been Granted Priority Review and Given a Target Regulatory Decision Date of November 30, 2022.
Scynexis Inc - Submission Has Been Granted Priority Review and Given a Target Regulatory Decision Date of November 30, 2022.